Expertise in
8
conditions

Dr. Howard Zaren

Surgical Oncology
Office
225 Candler Dr Ste 204, 
Savannah, GA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
8
conditions
Office
225 Candler Dr Ste 204, 
Savannah, GA 

Overview

Howard Zaren is a Surgical Oncologist in Savannah, Georgia. Dr. Zaren is highly rated in 8 conditions, according to our data. His top areas of expertise are Melanoma, Breast Cancer, Merkel Cell Carcinoma, Paget Disease of the Breast, and Mastectomy.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 114 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Surgical Oncology

Licenses

Surgery in GA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Office
225 Candler Dr Ste 204, Savannah, GA 31405
Other Locations
SJC Oncology Services Georgia LLC
225 Candler Dr Ste 100, Savannah, GA 31405

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

113 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Cancer Moonshot Biobank Research Protocol
Cancer Moonshot Biobank Research Protocol
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Other
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
View 8 Less Clinical Trials

5 Total Publications

Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium.
Journal: Lancet regional health. Americas
Published: April 20, 2022
Similar Doctors
Expertise in
20
conditions
Dr. William Burak
Surgical Oncology
Expertise in
20
conditions
Dr. William Burak
Surgical Oncology

Memorial Health University Physicians - Breast Care

4700 Waters Ave Bldg 100 Ste 405, 
Savannah, GA 
 (3.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Burak is a Surgical Oncologist in Savannah, Georgia. Dr. Burak is highly rated in 20 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Lymphadenectomy. Dr. Burak is currently accepting new patients.

Expertise in
16
conditions
Dr. James Garber
Surgical Oncology
Expertise in
16
conditions
Dr. James Garber
Surgical Oncology

Memorial Health Physicians - Surgical Care

4700 Waters Ave Bldg 400, 
Savannah, GA 
 (3.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Garber is a Surgical Oncologist in Savannah, Georgia. Dr. Garber is highly rated in 16 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Choledocholithiasis, Pancreatectomy, and Splenectomy. Dr. Garber is currently accepting new patients.

Expertise in
6
conditions
Dr. Leonard Henry
Surgical Oncology
Expertise in
6
conditions
Dr. Leonard Henry
Surgical Oncology

Nancy N. And J.C Lewis Cancer & Research Pavilion

225 Candler Dr, 
Savannah, GA 
 (0.1 miles away)
912-819-5704
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Henry is a Surgical Oncologist in Savannah, Georgia. Dr. Henry is highly rated in 6 conditions, according to our data. His top areas of expertise are Melanoma, Breast Cancer, Thyroid Cancer, Thyroidectomy, and Pancreatectomy.

Frequently Asked Questions about Dr. Howard Zaren

How do I make an appointment with Dr. Howard Zaren?

You can book an appointment with Dr. Howard Zaren by calling their office at 912-819-6804. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Howard Zaren a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Howard Zaren is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Howard Zaren specialize in?

While Dr. Howard Zaren is a Surgical Oncology, they have specific expertise in Melanoma, Breast Cancer, and Merkel Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Howard Zaren participate in research or clinical trials?

Yes. Dr. Howard Zaren has published 5 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Howard Zaren's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Howard Zaren accept my insurance?

Dr. Howard Zaren accepts most major insurance plans, including Blue Cross Blue Shield and CareSource. We recommend calling the office directly at 912-819-6804 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zaren's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile